Gustavsen Stefan, Olsson Anna, Oturai Annette B, Linnet Kristian, Thomsen Ragnar, Rasmussen Brian S, Jørgensen Christian F, Langkilde Annika R, Sorensen Per S, Sellebjerg Finn, Søndergaard Helle B
Department of Neurology, Danish Multiple Sclerosis Center, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
Department of Forensic Medicine, Section of Forensic Chemistry, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Eur J Neurol. 2023 Oct;30(10):3212-3220. doi: 10.1111/ene.15930. Epub 2023 Jul 7.
The endocannabinoid system (ECS) has been found altered in patients with multiple sclerosis (MS). However, whether the ECS alteration is present in the early stage of MS remains unknown. First, we aimed to compare the ECS profile between newly diagnosed MS patients and healthy controls (HCs). Next, we explored the association of the ECS, biomarkers of inflammation, and clinical parameters in newly diagnosed MS patients.
Whole blood gene expression of ECS components and levels of endocannabinoids in plasma were measured by real-time quantitative polymerase chain reaction and ultra-high-pressure liquid chromatography-mass spectrometry, respectively, in 66 untreated MS patients and 46 HCs.
No differences were found in the gene expression or plasma levels of the selected ECS components between newly diagnosed MS patients and HCs. Interferon-γ, encoded by the gene IFNG, correlated positively (ρ = 0.60) with the expression of G protein-coupled receptor 55 (GPR55), and interleukin1β (IL1B) correlated negatively (ρ = -0.50) with cannabinoid receptor 2 (CNR2) in HCs.
We found no alteration in the peripheral ECS between untreated patients with MS and HC. Furthermore, our results indicate that the ECS has a minor overall involvement in the early stage of MS on inflammatory markers and clinical parameters when compared with HCs.
已发现多发性硬化症（MS）患者的内源性大麻素系统（ECS）发生改变。然而，ECS改变是否存在于MS早期仍不清楚。首先，我们旨在比较新诊断的MS患者与健康对照者（HCs）的ECS特征。其次，我们探讨了新诊断的MS患者中ECS、炎症生物标志物和临床参数之间的关联。
分别采用实时定量聚合酶链反应和超高压液相色谱-质谱法，测定了66例未经治疗的MS患者和46例HCs的全血中ECS成分的基因表达及血浆中内源性大麻素的水平。
新诊断的MS患者与HCs之间，所选ECS成分的基因表达或血浆水平未发现差异。在HCs中，由IFNG基因编码的干扰素-γ与G蛋白偶联受体55（GPR55）的表达呈正相关（ρ = 0.60），白细胞介素1β（IL1B）与大麻素受体2（CNR2）呈负相关（ρ = -0.50）。
我们发现未经治疗的MS患者与HCs的外周ECS无改变。此外，我们的结果表明，与HCs相比，ECS在MS早期对炎症标志物和临床参数的总体影响较小。
